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Abstract
Targeting tumors using miniature antibodies is a novel and attractive therapeutic approach, as
these biomolecules exhibit low immunogenicity, rapid clearance, and high targeting specificity.
However, most of the small-sized antibodies in existence do not exhibit marked anti-tumor effects, which limit their use in targeted cancer immunotherapy. To overcome this difficulty in
targeting multiple biomarkers by combination therapies, we designed a new bifunctional antibody,
named MaAbNA (multivalent antibody comprised of nanobody and affibody moieties), capable of
targeting EGFR1 and HER2, which are widely overexpressed in a variety of tumor types. The
small-sized (29 kDa) MaAbNA, which was expressed in E.coli, consists of one anti-EGFR1 nanobody and two anti-HER2 affibodies, and possesses high affinity (KD) for EGFR1 (~4.1 nM) and HER2
(~4.7 nM). In order to enhance its anti-tumor activity, MaAbNA was conjugated with adriamycin
(ADM) using a PEG2000 linker, forming a new complex anticancer drug,
MaAbNA-PEG2000-ADM. MaAbNA exhibited high inhibitory effects on tumor cells
over-expressing both EGFR1 and HER2, but displayed minimal cytotoxicity in cells expressing low
levels of EGFR1 and HER2. Moreover, MaAbNA-PEG2000-ADM displayed increased tumoricidal
effects than ADM or MaAbNA alone, as well exhibited greater antitumor efficacy than EGFR1
(Cetuximab) and HER2 (Herceptin) antibody drugs. The ability of MaAbNA to regulate expression
of downstream oncogenes c-jun, c-fos, c-myc, as well as AEG-1 for therapeutic potential was
evaluated by qPCR and western-blot analyses. The antitumor efficacy of MaAbNA and its derivative MaAbNA-PEG2000-ADM were validated in vivo, highlighting the potential for use of MaAbNA
as a highly tumor-specific dual molecular imaging probe and targeted cancer therapeutic.
Key words: EGFR1, HER2

Introduction
Epidermal growth factor receptors (EGFRs) are a
sub-family of four transmembrane receptor tyrosine
kinases (RTKs), EGFR1-4 (HER1-4). A variety of extracellular binding ligands, such as EGF, bind and
activate HER1, HER3 and HER4, whereas HER2 is
activated via dimerization with other EGFR family
members [1- 3]. EGFR molecules can mediate cell proliferation as monomers, but their mitogenic effects can

be exacerbated via inter-receptor interactions. EGFR1
and HER2 structures (Fig. 1) contain a tyrosine kinase
domain that is responsible for activation of downstream signaling pathways, leading to expression of
genes related to cell cycle progression, such as c-jun,
c-fos and c-myc. But this activation (PI3K/Akt and
Ras/Raf/MEK/ERK) could be inhibited to some extent by either anti-EGFR1 antibodies (Matuzumab,
http://www.thno.org
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Cetuximab or anti-EGFR1 nanobody) [4, 5] or anti-HER2 antibodies (Herceptin) [6, 7]. Over-expression
of EGFR1 and/or HER2 has been observed in a variety of human tumors, and these individual receptors
are important diagnostic indicators as well as promising targets for anti-tumor therapy [8- 14]. However,
accumulating evidence indicates that inhibiting the
activity of individual EGFRs is insufficient to achieve
complete clinical response. For example, the therapeutic effect of treating tumors with HER2 monoclonal antibody 4D5 can be reversed by EGF-related
peptides [15]. The complex mechanisms of EGFR
signaling pathway activation, both autonomous and
dependent, have necessitated the development of
combination therapies targeting multiple EGFRs to
achieve synergetic effects compared to targeting a
single receptor [16, 17]. Recently, the bifunctional
small molecule tyrosine kinase inhibitor (TKI) Lapatinib, which targets both EGFR1 and HER2, was
shown to exhibit enhanced therapeutic efficacy in
HER2-positive breast cancers [18], although its deficiency in tumor targeting remains a limitation [19].

Figure 1. The mechanism of MaAbNA blocking the EGFR1 and HER2 signaling
pathways.

In contrast to small molecule TKIs, which lack
tumor targeting specificity, bivalent and bispecific
antibodies exhibiting high tumor affinity are being
widely applied in tumor targeting and therapeutics
[20]. However, a limitation of targeted antibodies,
which consist of two monoclonal antibodies (mAbs),
is their large size, which results in subpar biodistribution profiles and limits their penetration into tumor
tissue, yielding low tumor-specific accumulation [21].
To circumvent this issue, incomplete antibody fragments are being investigated as component forming
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bifunctional proteins which may exhibit enhanced
tumor penetration. Baeuerle and others reported the
design and construction of several bispecific antibodies suitable for tumor targeting through the use of
single chain variable fragment (scFv) or CDR3 regions
of mAbs [22- 24]. Unfortunately, due to the lack of
functional units possessed by the complete antibody,
most of these miniature bivalent antibodies do not
exhibit appreciable biological activity with respect to
tumor cell killing [25].
Affibody molecules, derived from staphylococcal protein A, are attractive surrogates for full-size
antibodies in tumor targeting applications due to their
small size and low immunogenicity [26, 27]. The single protein chain of affibodies facilitates direct fusion
with various proteins. Similarly, nanobodies are small
biomolecules derived from the heavy-chain of camelidae family [28, 29]. Although these antibodies are devoid of light chains, their antigen-binding ability is
retained by integrating the functions of VH and VL
into a single immunoglobulin (Ig) variable region
termed VHH, or nanobody. Unlike mAbs, these
fragments, which are composed of a single Ig fold and
lacking Fc fragments, expose hydrophobic patches
that bind to receptors without the need to undergo
partial unfolding. Additionally, the lack of protease-sensitive peptide sequences confers higher in vivo
stability to nanobodies compared to single-chain Fv
fragments. Until now, in both preclinical and clinical
settings, the immunogenicity of nanobodies has not
exceeded predicted levels, presumably due to their
high degree of homology with human VH domains
[30]. Genes encoding these nanobodies can be easily
engineered to obtain multivalent structures, and can
be fused and recloned into other proteins. Henegouwen group constructed a biparatopic antibody
by using two anti-EGFR1 nanobodies, which was effective at inhibiting tumor cell growth in a xenograft
model of A431 cells in athymic mice [31]. Additionally,
dimeric
HER2-specific
affibodies
and
EGFR1/HER2 bispecific antibodies, consisting of
EGFR1 and/or HER2-specific affibodies, were designed by the Lennartsson [32] and Stahl [33] groups,
respectively, and their in vitro efficacy were evaluated
using SKOV-3 ovarian cancer cells. To date, all reported bivalent nanobodies and affibodies have exhibited impressive tumor targeting ability, and have
uses in tumor imaging applications and as tumor
ligands for drug delivery [34- 37]. However, no study
was reported to fuse affibody with nanobody to form
bispecific complex for enhanced targeting and antitumor efficacy, which motivate us to construct an
affibody-nanobody complex for comprehensive tumor targeting and therapeutic efficacy investigation.
In this study, we constructed a novel bispecific
http://www.thno.org
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antibody, MaAbNA, by fusing the ZHER2:4 affibody
[38] to the anti-EGFR1 nanobody 7D12 [39]. Two affibody molecules were used in this construction since
bivalent affibodies are more effective in tumor imaging and targeting than monovalent affibodies [40, 41].
In order to further enhance their tumoricidal activity,
the widely used anticancer drug adriamycin (ADM)
was conjugated to MaAbNA using a PEG2000 linker.
The novel bispecific complex was intensively investigated both in vitro and in vivo.

Materials and methods
Materials
The pET22b vector and E.coli BL21 were purchased from Novagen and American Type Culture
Collection (ATCC, USA), respectively. His GraviTrap,
Sephadex G-15, Sephadex G-75, Sephadex G-100 and
mono Q anion-exchange columns were obtained from
GE Healthcare. The hydrophilic near-infrared dye
ICG-Der-02 (MPA) (EX/EM: 760nm/830nm) was
prepared in our laboratory [42]. Rhodamine B (MW
479.01, EX/EM: 540nm/625nm), 1-ethyl-3-(3-dimethylamino-propyl)
carbodiimide
hydrochloride
(EDCI, MW 191.07), N-hydroxy-succinimide (NHS,
MW 115.08), N, N-Diisopropylethylamine (DIPEA,
MW 129.25) and NaBH3CN (MW 62.84) were purchased
from
Aladdin.
RPMI-1640,
3-(4,
5-dimethylthialzol-a-yl)-2,
5-diphenyltetrazolium
bromide (MTT), fetal bovine serum (FBS), penicillin,
streptomycin, and trypsin-EDTA were purchased
from commercial sources. Adriamycin hydrochloride
(ADM.HCl, MW 579.99) was purchased from Beijing
Huafenglianbo Technology Co. Ltd. The EGFR1 antibody (Cetuximab) was purchased from Merck, and
the HER2 antibody (Herceptin) was from Roche. The
6×His-tag
ELISA
kit
was
from
Abcam.
NHS-PEG2000-ALD was from Xiamen Saigeluobang
Biological Technology CO. Ltd. Trizol reagent, Reverse Transcription kit, and qPCR Master Mix were
obtained from Promega. Restriction endonucleases
(NcoI and BamHI) and T4 DNA Ligase were from
Fermentas. The anti-EGFR1 nanobody 7D12 and
ZHER2:4 affibody both tagging with 6×His were expressed and purified by Nanjing Jinsirui Biological
Technology Co. Ltd. EGF with 6×His-tag was purchased from KeyGEN Biological Technology Co. Ltd.
ON-TARGET plus siRNA SMART pools against
EGFR1, HER2, c-myc, AEG-1 and negative control
were from GE Dharmacon. Primers, BCA kits, all
primary antibodies used in Western blots, and other
reagents were from the Shanghai Chemical Reagent
Company.
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Design and construction of the bispecific
antibody MaAbNA
Design and Expression of MaAbNA
The ZHER2:4 affibody and anti-EGFR1 nanobody 7D12 were used as the anti-HER2 antibody and
the anti-EGFR1 antibody, respectively. The receptor-binding domains were linked with G4S (Fig. 2A),
an established linker with high flexibility and hydrophobicity [43]. The gene encoding the sequence of
NcoI-MaAbNA-BamHI was purchased from Nanjing
Jinsirui biological technology company. NcoI and
BamHI sites were designed for insertion into the
pET22b vector, and the gene sequence of MaAbNA
was optimized following the codon usage bias of
E.coli BL21. The amino acid sequence of the MaAbNA
is show in Fig. 2B.
After double restriction enzyme digestion, the
gene encoding the sequence of MaAbNA was inserted
into the expression plasmid pET22b encoding the
His6 tag (Fig. 2C). The recombinant plasmid was then
transformed into E.coli strain BL21, where the
MaAbNA molecule was expressed as a His6-tagged
protein. Briefly, a pre-culture of E.coli cells was inoculated in fresh LB medium containing 100 mg/L ampicillin and grown in flasks at 37 °C with shaking until
an attenuance (OD600) of ~0.6 was attained. Protein
expression was induced by subsequent addition of
IPTG to a final concentration of 1 mM. After culturing
for a further 5 h at 37 °C, cells were harvested by centrifugation at 8000 rpm for 10 min at 4 °C. The cell
pellet was resuspended in Lyse buffer (100 mM
Tris/HCl, pH 8.0) and disrupted by sonication. After
centrifugation at 13000 rpm for 30min at 4 °C, the
pellet was dissolved in binding buffer (8 M urea, 10
mM Tris/HCl, pH 8.0), and purified on a His GraviTrap column. The Ni-column was washed with a
concentration gradient of imidazole washing buffers
(0, 5, 10, 20, 50, 100, 200, 500 mmol/L imidazole, 8
mol/L urea, Tris/HCl, pH 8.0) to obtain the optimal
buffer solution. Incorrectly folded protein bounds to
the column was eluted with imidazole buffer (100 mM
imidazole, 8 M urea, Tris/HCl, pH 8.0), and refolding
of the eluted protein was accomplished through dialysis with a concentration gradient of urea buffers (6, 4,
2, 1, 0.5, 0 mol/L urea, Tris/HCl, pH 8.0). Purification
of the renatured protein was performed using Sephadex G-75 columns and protein was quantified
using a BCA kit. To confirm the purity and correct
molecular weight of the protein, the product was analyzed by SDS/PAGE, and the His6-tagged protein
was identified by Western blot analysis using an Anti-His monoclonal antibody.

http://www.thno.org
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Synthesis of MaAbNA-PEG2000-ADM
MaAbNA-PEG2000-ADM was synthesized in a
two-step process, as shown in Supplementary Material: Fig. S1. NHS-PEG2000-ALD (2 mg), ADM (0.6
mg) and DIPEA (0.2 mg) were first dissolved in 10 ml
DMF, and the solution was stirred for 12 hours. After
purification on a Sephadex G-15 column, the reaction
product ADM-PEG2000-ALD was obtained. Second,
ADM-PEG2000-ALD (0.2 mg), MaAbNA (15 mg) and
NaBH3CN (0.01 mg) were dissolved in 10 ml PBS (pH
6.5), the solution was stirred at 4 °C for 24 hours, and
the ALD (propionaldehyde) group was mostly conjugated to the N-terminal amino of MaAbNA through
reductive amination. Using a mono Q anion-exchange
column, we obtained the purified product
MaAbNA-PEG2000-ADM, the purification of which
was determined by HPLC using a Sephadex G100
column.

Fluorescence labeling
The constructed protein MaAbNA along with
the His6-tagged anti-EGFR1 nanobody 7D12,
ZHER2:4 affibody and EGF were labeled with the
visible fluorescence dye RhodamineB for in vitro cell
study. By controlling the feed ratios and reaction time,
each antibody or ligand had a similar labeling efficiency with respect to Rhodamine B (molar ratio was
approximately 1: 2), and at the same molar concentration, demonstrated equivalent fluorescence efficiency.
For in vivo study, the home built near infrared
dye MPA (EX/EM: 760nm/830nm) was used to replace RhodamineB for the labeling to all the ligands
with the similar method.

In vitro studies
Cell lines
Human tumor cell lines (MDA-MB-231, A549
and MCF-7) and the normal human pulmonary epithelial cell line L2 were all purchased from ATCC and
used for evaluation of MaAbNA cytotoxicity and cell
binding affinity. MDA-MB-231 and MCF-7 cells were
cultured in DMEM medium supplemented with 10%
FBS, 100 U/ml penicillin and 100 mg/ml streptomycin, while A549 and L2 were cultured in RPMI-1640
medium supplemented as for MDA-MB-231 and
MCF-7. Cells were maintained at 37 °C in humidified
atmosphere containing 5% CO2.

Primers
The mRNA sequences of the EGFR1 [GenBank:
NM_005228.3
(human)],
HER2
[GenBank:
NM_004448.3
(human)],
c-jun
[GenBank:
NM_002228.3
(human)],
c-fos
[GenBank:
NM_005252.3 (human)], and the housekeeping gene
GAPDH [GenBank: NM_002046.5 (human)] were ob-
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tained from the nucleotide database at the National
Center for Biotechnology Information (NCBI) website.
Oligonucleotide primers were designed using Primer
6 and are listed in Table 1.
Table 1. Oligonucleotides sequence of 5’ and 3’ primers.
Target gene
EGFR(Hum)
HER2(Hum)
c-jun(Hum)
c-fos(Hum)

5’ primer
CTGTCCTGTGATGCTGTAA
TCTTGAATGTGGTGGTGTAA
TGGTAGCAGATAAGTGTTGA
GCTGACTGATACACTCCAA

3’ primer
ACTGCCTGGTCTCTGAAT
TTGCTTGAACTGCTTGAAC
CGTGGAGAAGCCTAAGAC
CTGCTGATGCTCTTGACA

EGFR1 and HER2 expression level analysis in tumor
cells
Briefly A549, MDA-MB-231, and MCF-7 cells
were cultured for 24 hours in 6-well dishes at 37 °C.
Total RNA was extracted from cells using Trizol reagent, and was dissolved in diethylpyrocarbonate
(DEPC)-treated water. Total RNA was adjusted to a
final concentration of 0.1 µg/ml, and reverse transcribed using a Reverse Transcription kit. cDNA
samples were mixed with primer pairs (EGFR1, HER2
or GAPDH) and a qPCR Master Mix were prepared
for subsequent qPCR analyses using the StepOne plus
Real-Time qPCR system. The results were analyzed
by using StepOne Software.
To further investigate the EGFR1 and HER2 expression level in tumor cells, Western blot analysis
was performed. After 48 hour incubation, A549,
MDA-MB-231, and MCF-7 cells were lysed in lysis
buffer. Proteins were separated on a 12%
SDS-polyacrylamide gel and transferred onto polyvinylidene difluoride membranes (Millipore, USA).
Membranes
were
blocked
with
10%
milk/Tris-buffered saline/0.1% Tween 20 for 2 h, incubated with primary antibodies (EGFR1, HER2 and
β-actin), and incubated with fluorescent secondary
antibody for 1 h. Fluorescence was visualized with
enhanced chemiluminescence detection system
(Amersham, UK), and protein expression was quantified by densitometry analysis using Quantity One
software (BioRad).

In vitro tumor cells targeting
To assess the in vitro targeting ability, MaAbNA
was compared to the positive control (anti-EGFR1
nanobody 7D12, ZHER2:4 affibody) in different tumor
cell lines using immunofluorescence analysis. Cells
were seeded in dishes suitable for confocal microscopy, incubated for 24 hours, then incubated for 2
hours in 1 mL of RhodamineB-MaAbNA, RhodamineB-anti-EGFR1 nanobody 7D12 or RhodamineB-ZHER2:4 affibody (5 μmol/L). After washing
with PBS, cells were imaged by a laser confocal mihttp://www.thno.org
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croscope (Olympus FV1100).
To elucidate the targeting mechanism of
MaAbNA, blocking experiments with unlabeled (free)
MaAbNA were conducted on all cell lines cultured at
37 °C for 24 hours. Free MaAbNA (0.25 mmol/L) was
added to the cells 30min prior to incubation with
RhodamineB-MaAbNA,
RhodamineB-anti-EGFR1
nanobody 7D12 or RhodamineB-ZHER2:4 affibody
for a further 2 hours. After washing with PBS, the cells
were imaged using laser confocal microscopy.
Flow cytometric analysis of the FL2 mean fluorescent intensity (MFI) of the cells was used to perform a quantitative determination of the tumor targeting ability of MaAbNA.

Competition ELISA method for antibody affinity determination
The MaAbNA antibody (approximately 0.5
nmol/L) was combined with increasing concentrations of EGFR1 or HER2 antigen (0, 500, 1000, 1500
and 2000 nmol/L), and incubated at room temperature for 18 h to achieve equilibrium between free
MaAbNA and MaAbNA-receptor complexes. Subsequently, reaction mixtures were added into wells
precoated with antigen (over-dose), and incubated for
40 min to ensure that free MaAbNA was completely
bound to the immobilized antigen. After removing
the reaction mixture, wells were washed three times,
and the amount of MaAbNA bound coated antigen
were quantitated using a Standard ELISA (according
to the instructions provided by the manufacturer of
the 6×His-tag ELISA Kit). The affinity of MaAbNA
binding to EGFR1 or HER2 was calculated using the
following equation KD= lAilMi/(lM0-lMi) [44], where lAi
is the molar concentration of antigen combined with
MaAbNA, lMi is the molar concentration of free
MaAbNA with a combined antigen concentration of
lAi, and lM0 is the molar concentration of free MaAbNA
in the absence of antigen, and (lM0-lMi) represents the
molar concentration of the MaAbNA-antigen complex
at equilibrium. Additionally, the affinity of
MaAbNA-PEG2000-ADM binding to EGFR1 or HER2
was measured as the same protocol. As a reference,
the affinity of the anti-EGFR1 nanobody 7D12 for
EGFR1 and ZHER2:4 affibody binding to HER2 was
also calculated using this method.

In vitro competitive inhibition of EGF binding
As the intrinsic ligand EGF will bind to EGFR1 of
tumor cells and thus accelerate its proliferation, the
EGF binding inhibition was carried out. RhodamineB-EGF (5 μmol/L) was added to tumor cells
(A549 or MDA-MB-231) growing in confocal-compatible dishes, in the absence or presence of
free MaAbNA (250 μmol/L). After 2 hour incubation
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at 37 °C, cells were washed with PBS and imaged by
laser confocal microscopy.
To further verify the ability of MaAbNA to
compete with EGF for binding to EGFR1, A549 and
MDA-MB-231 tumor cells were trypsinized from
12-well cell culture plates, resuspended in PBS, and
incubated with RhodamineB-EGF (5 μmol/L). Increasing concentrations of free MaAbNA (5, 10, 25, 50,
250 µmol/L) were added simultaneously to compete
for EGFR1 binding, and the MFI of the cells was detected by flow cytometry.

In vitro therapeutic efficacy
Cell viability assays were carried out to evaluate
the therapeutic efficacy of MaAbNA and
MaAbNA-PEG2000-ADM in EGFR1-positive and/or
HER2-positive cells, A549 and MDA-MB-231, as well
as their toxicity toward an EGFR1-negative and
HER2-negative
cell
line
(MCF-7)
and
a
non-tumorigenic cell line (L2). The commercial antibody drugs (anti-EGFR1 Cetuximab and anti-HER2
Herceptin) and the widely used anticancer drug
adriamycin (ADM) were used as positive controls.
After
a
24
hour
incubation,
MaAbNA,
MaAbNA-PEG2000-ADM, Cetuximab, Herceptin or
increasing concentrations of ADM (0.1, 0.2, 0.4, 0.8,
1.6, and 3.2 μmol/L) were added to the cells growing
in 96 well plates (n= 6), which were then incubated for
48 hours. MTT solution (20 mL; 5 mg/mL) was added
to each well after incubation and the absorbance of the
solution was measured at 490 nm using a multiwell
plate reader.
To further investigate the EGFR1 and HER2 targeted antitumor efficacy of MaAbNA and
MaAbNA-PEG2000-ADM, EGFR1- or HER2- knockdown A549 cells were constructed. The RNA interference assay was done according to the protocols
provided by the manufacturer of the ON-TARGET
plus siRNA SMART pools, and the knockdown effects
were evaluated by western-blot analyses. At 24-hour
post-transfection of EGFR1 or HER2 siRNA, A549
cells were seeded into 96-well plates. After 24-hour
incubation, MaAbNA and MaAbNA-PEG2000-ADM
(1 or 2 μmol/L) were added to the cells, which were
then incubated for 48 hours to measure the inhibiting
rate of cell proliferation.

Oncogene regulation analysis in tumor cells by
qPCR
Briefly A549, MDA-MB-231, and MCF-7 cells
were cultured for 24 hours in 6-well dishes at 37 °C in
the presence of either MaAbNA or anti-EGFR1
nanobody 7D12 (3 μmol/L); non-treated cells were
included as a negative control. Total RNA was extracted from cells and tumor tissues using Trizol reahttp://www.thno.org
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gent, and was dissolved in diethylpyrocarbonate
(DEPC)-treated water. Total RNA was adjusted to a
final concentration of 0.1 µg/ml, and reverse transcribed using a Reverse Transcription kit. cDNA
samples were mixed with primer pairs (c-jun, c-fos or
GAPDH) and a qPCR Master Mix were prepared for
subsequent qPCR analyses using the StepOne plus
Real-Time qPCR system. The results were analyzed
by using StepOne Software.

Western blot analysis for signaling pathway
proteins
A549 cells were seeded in 6-well plates and incubated for 48 hours with MaAbNA (3 μmol/L) or
anti-EGFR1 nanobody 7D12 (3 μmol/L). Cells were
divided into three groups respectively for detection of
Akt S473 phosphorylation (pAkt), c-myc, and AEG-1.
Cells transfected with c-myc or AEG-1 siRNA were
used as controls for c-myc or AEG-1 expression; untreated cells were included as a control for each
group. MDA-MB-231 cells treated with MaAbNA (3
μmol/L) or anti-EGFR1 nanobody 7D12 (3 μmol/L)
were also used for detection of phosphorylated Akt
(pAkt). After various treatments for the indicated periods of time, cells were lysed in lysis buffer; for
analysis of phospho-protein expression, cells were
lysed in lysis buffer supplemented with protease inhibitor cocktail, 1 mM sodium fluoride, and 1 mM
sodium orthovanadate. Proteins were separated on a
12% SDS-polyacrylamide gel and transferred onto
polyvinylidene difluoride membranes (Millipore,
USA). Membranes were blocked with 10%
milk/Tris-buffered saline/0.1% Tween 20 for 2 h, incubated with primary antibodies (pAkt, c-myc,
AEG-1, Akt, or β-actin), and incubated with fluorescent secondary antibody for 1 h. Fluorescence was
visualized with enhanced chemiluminescence detection system (Amersham, UK), and protein expression
was quantified by densitometry analysis using Quantity One software (BioRad).

Animal experiments
Animal models
All animal experiments were carried out in
compliance with the Animal Management Rules of
the Ministry of Health of the People's Republic of
China. A549, MDA-MB-231 and MCF-7 cells (5×106)
were injected subcutaneously into the upper axillary
fossa of nude mice (Charles River Laboratories, n = 10
per group). When tumor size reached 0.3- 0.4 cm in
diameter, mice were used for NIR imaging and
treatment. For pharmacokinetic studies, Lewis rats
were used (Charles River Laboratories, n= 10 per
group).
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Tumor targeting in tumor bearing mice
To investigate the dynamic distribution and tumor targeting ability of MaAbNA in nude mice,
MPA-MaAbNA (50 nmol/kg) and the positive control
(MPA-anti-EGFR1 nanobody 7D12, MPA-ZHER2:4
affibody) were injected intravenously and the fluorescence imaging was performed at various time
points post-injection using an NIR imaging system.
Free MaAbNA (2.5 μmol/kg) was used in blocking
experiments. The tumor/normal tissue ratios (T/N
ratio) were analyzed and compared using the analysis
region of interests (ROI) function.

In vivo competitive inhibition of EGF
tumor-binding
To investigate the ability of MaAbNA to compete with intrinsic EGF for binding to EGFR1 in vivo,
A549 and MDA-MB-231 tumor-bearing mice were
divided into 2 groups, one of which received
MPA-EGF (50 nmol/kg) via intravenous injection
while the other received MPA-EGF (50 nmol/kg) together with free MaAbNA (2.5 μmol/kg) in order to
evaluate competitive blocking. Fluorescence imaging
of the mice was performed using an NIR imaging
system at various time points post-injection, and the
tumor/normal tissue ratios (T/N ratio) were analyzed and compared using the analysis region of interests (ROI) function.

Pharmacokinetics of MaAbNA and
MaAbNA-PEG2000-ADM
Lewis rats were divided into 2 groups (n= 6) for
intravenous administration of MaAbNA and
MaAbNA-PEG2000-ADM (300 nmol/kg). At 0.5, 2, 4,
6, 8, 12, 24, 48 and 72 hours post injection, blood samples were obtained from the fossa orbitalis, and serum concentrations
of
MaAbNA
and
MaAbNA-PEG2000-ADM were quantified using a 6×
His-tag ELISA Kit. Serum drug levels were analyzed
using WinNonlin pharmacokinetic software.

In vivo antitumor efficacy
A549 tumor-bearing mice were randomly divided into 6 groups (n= 6 per group), and treated
every other day for 15 days via tail vein injection with
0.2mL of the following: (A) Saline (control group); (B)
ADM (400 nmol/kg); (C) Cetuximab (400 nmol/kg);
(D) Herceptin (400 nmol/kg) (E) MaAbNA (400
nmol/kg); and (F) MaAbNA-PEG2000-ADM (400
nmol/kg). The therapeutic efficacies and systematic
toxicities of MaAbNA and MaAbNA-PEG2000-ADM
were evaluated based on daily measurements of tumor volume and body weight. Upon completion of
treatment (15 days), mice were sacrificed and the resected tumors were photographed, and along with
http://www.thno.org
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hearts and kidneys to be processed from histologic
examination.

Statistical analysis
Data were expressed as mean ± SD. Statistical
analysis was conducted using a Students t-test, with
statistical significance assigned to a P value lower
than 0.05.

Results
Identification and characterization of
MaAbNA
The experimental design and method of
MaAbNA expression are shown in Figures 2A and 2C.
MaAbNA was initially purified by His GraviTrap
column, with lanes 1- 8 representing the proteins
eluted from His GraviTrap column with wash buffer
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containing increasing concentrations of imidazole (0,
5, 10, 20, 50, 100, 200 and 500 mmol/L imidazole, respectively) (Fig. 2D). The intense signal in lane 6 with
an approximate molecular weight of 29 kDa indicates
that the target protein constitutes a large portion of
the crude products. The crude product was further
purified using a Sephadex G-75 column and subsequently analyzed by SDS-PAGE (Fig. 2E). Gray level
difference analysis indicated purity of up to 90%. To
further confirm the identification of the target protein,
Western blot analysis using an anti-His antibody detected a protein with molecular weight of 29 kDa as
our targeted protein (Fig. 2F). MaAbNA exhibited a
single absorption peak at 280 nm (Fig. 2G). Using the
BCA kit, we determined the protein concentration of
the fermentation liquid to be 1.7 mg/L.

Figure 2. Design (A) and amino sequence (B) of MaAbNA. C, construction and expression of MaAbNA. SDS-PAGE analysis of MaAbNA purified by His GraviTrap
column (D), then by Sephadex G-75 (E). F, Western Blot analysis of MaAbNA using anti-His6 antibody. G, the absorption spectra of MaAbNA and
MaAbNA-PEG2000-ADM. H, HPLC map of MaAbNA-PEG2000-ADM.
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Figure 3. A, qPCR analysis of EGFR1/GAPDH and HER2/GAPDH in A549, MDA-MB-231 and MCF-7 cancer cells. B, Western Blot analysis of EGFR1 and HER2
expressing in A549, MDA-MB-231 and MCF-7 cells. Data are given as mean±SD (n=5).

Identification and characterization of
MaAbNA-PEG2000-ADM

HER2. Gene expression results were confirmed by
Western blot analysis as shown in Fig. 3B.

Due to the presence of NaBH3CN, the ALD
(propionaldehyde) group can be conjugated to the
only primary amine groups in MaAbNA through reductive amination [45, 46]. In the peptide chain of
MaAbNA, the only primary amines are the ε-amino
groups in the side chain of lysine and N terminal
α-amino groups. Additionally, the N terminal
α-amino is more nucleophilic than the ε-amino at pH
6.5 [47], providing higher selectivity for the N terminal α-amino to be conjugated to ALD group through
reductive amination. All of these had provided a feasible scheme to make an N terminal site-directed
PEGylation of MaAbNA, with a final product of
MaAbNA-PEG2000-ADM (Supplementary Material:
Fig. S1).
As shown in Fig. 2G, MaAbNA-PEG2000-ADM
exhibits three absorption peaks at 243 nm (PEG2000),
280 nm (MaAbNA), and 479 nm (ADM), confirming
successful synthesis. In addition, a single peak of
MaAbNA-PEG2000-ADM with a retention time of
13.1 min is observed by HPLC (Fig. 2H), reflecting a
purity
of
greater
than
90%.
Moreover,
MaAbNA-PEG2000-ADM was quantified using a 6×
His-tag ELISA Kit, while the ADM component was
quantitated based on an ADM (OD 479) standard
curve, which together indicated a modified
ADM/MaAbNA ratio of 1: 1.

In vitro tumor-targeting ability

Expression level of EGFR1 and HER2 in tumor
cells
To assess the correlation between the combined
EGFR1/HER2 expression and the targeting and
therapeutic abilities of MaAbNA, mRNA transcription levels of EGFR1 and HER2 were investigated in
tumor cell lines (A549, MDA-MB-231, MCF-7) (Fig.
3A). The expression of EGFR1 and HER2 in the different cancer cells decreased in the following order:
A549 > MDA-MB-231> MCF-7; MDA-MB-231 and
MCF-7 cells did not exhibit significant expression of

To investigate the specificity of the small-sized
MaAbNA antibody for tumor cells over-expressing
EGFR1 and/or HER2, we evaluated the binding of
RhodamineB-MaAbNA to A549 cells (EGFR1 and
HER2 positive), MDA-MB-231 cells (EGFR1 positive),
and MCF-7 cells (EGFR1 and HER2 negative). RhodamineB-anti-EGFR1 nanobody 7D12 and RhodamineB-ZHER2:4 affibody were included as positive
controls. The fluorescence intensity of A549 cells incubated with RhodamineB-MaAbNA was higher than
that incubated with RhodamineB-anti-EGFR1 nanobody 7D12 or RhodamineB-ZHER2:4 affibody, but the
fluorescence intensity of MDA-MB-231 cells incubated with RhodamineB-MaAbNA was similar to that
incubated with RhodamineB-anti-EGFR1 nanobody
7D12 (Fig. 4A). The mean fluorescence was illustrated
in Fig. 4B. Moreover, tumor cell lines overexpressing
EGFR1 (A549 and MDA-MB-231) exhibited higher
fluorescence intensity than MCF-7 cells (Figs. 4A, B).
Pre-treatment with free MaAbNA inhibited the binding
of
RhodamineB-MaAbNA,
RhodamineB-anti-EGFR1 nanobody 7D12 and RhodamineB-ZHER2:4 affibody (Fig. 4), confirming the
binding of MaAbNA and its ability to selectively target cell membrane receptors (EGFR1 and HER2) on
A549 and MDA-MB-231 cells..
To quantitatively assess cellular binding of
RhodamineB-MaAbNA to A549, MDA-MB-231, and
MCF-7 cells, we performed flow cytometric analysis
under blocking and non-blocking conditions (Fig. 5).
The mean fluorescence intensity (MFI) in the tumor
cells decreased in the following order: A549 (MFI:
446)> MDA-MB-231 (MFI: 170)> MCF-7 (MFI: 58),
consistent with the receptor expression levels. In addition, A549 and MDA-MB-231 exhibited a much
higher MFI than their blocked counterparts, indicating the specificity of MaAbNA to EGFR1 and HER2
receptors.
http://www.thno.org
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Quantitative affinity determination by
competitive ELISA assay
To further confirm the specificity of MaAbNA to
EGFR1 and HER2, the competitive ELISA was performed. As shown in Supplementary Material: Fig.
S2A, increasing concentration of antigen (lAi) EGFR1
induced a linear increase in combined/free ratio of
MaAbNA [(lM0- lMi)/lMi] (with R2 > 0.998),
which ensured the accuracy of the affinity coefficient
KD calculated as KD= lAilMi/(lM0-lMi). The affinity values of MaAbNA, MaAbNA-PEG2000-ADM and anti-EGFR1 nanobody 7D12 binding to EGFR1 are ~4.1,
~6.9 and ~3.5 nM, respectively. From Supplementary
Material: Figure S2B, the affinity value of MaAbNA,
MaAbNA-PEG2000-ADM and ZHER2:4 affibody
binding to HER2 were calculated as ~4.7, ~7.2 and
~47.9 nM, respectively.
Each MaAbNA molecule is comprised of one
anti-EGFR1 nanobody and two ZHER2:4 affibodies,
and exhibits an EGFR1 binding affinity similar to an-

386
ti-EGFR1 nanobody, indicating that the activity of the
EGFR1 binding site was not significantly impaired by
fusion of the proteins. In addition, the HER2 affinity
of the bivalent ZHER2 domains of MaAbNA (~4.70
nM) showed a significant improvement compared to
the monovalent affibody (~47.9 nM), which confirmed
the correct design of double HER2 targeting domains.
Furthermore, compared with free MaAbNA (~4.1 nM
for
EGFR1
and
~4.7
nM
for
HER2),
MaAbNA-PEG2000-ADM exhibited similar affinity to
EGFR1 (~6.9 nM) and HER2 (~7.2 nM), demonstrating
that the activities of the EGFR1 and HER2 binding
sites were not significantly impaired by the
PEG2000-ADM conjugation.
It was noticed that the KDs of the anti-EGFR1
nanobody 7D12 and ZHER2:4 affibody (~3.5 and
~47.9 nM) were similar to that measured by Biacore
(~2.3 and ~50 nM) [38, 48], confirming that competition ELISA is an effective method for evaluating antibody affinity [49, 50].

Figure 4. A, laser confocal fluorescence microscopy images of cells (A549, MDA-MB-231 and MCF-7) incubated with different fluorescent probes (MaAbNA,
anti-EGFR1 nanobody 7D12 and ZHER2:4 affibody), with or without blocking dose of free MaAbNA. B, mean fluorescence intensity of cells treated with the three
fluorescent probes, while MaAbNA-treated cells were compared to the block. C, mean fluorescence intensity of cells treated with anti-EGFR1 nanobody 7D12 and
ZHER2:4 affibody probes, compared to the blocking by free MaAbNA. Data are given as mean±SD (n=5). *P <0.05.
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Figure 5. A, quantitative cellular binding (A549, MDA-MB-231 and MCF-7) of MaAbNA probe, additionally compared with the block. B, mean fluorescence intensity
of MaAbNA-treated cells with different EGFR1+HER2 expression level. Data are given as mean±SD (n=5).

In vitro competitive inhibition of EGF binding
As the intrinsic EGF will bind to EGFR1 of tumor
cells and thus accelerate its proliferation, the EGF
binding inhibited by MaAbNA was performed here.
As shown in Figures 6A and 6B, free MaAbNA effectively inhibited the cellular binding of RhodamineB-EGF. Furthermore, as the concentration of
MaAbNA increased, the MFI of A549 and
MDA-MB-231 treated simultaneously with RhodamineB-EGF gradually decreased (Figs. 6C, D),
demonstrating a dose-dependent effect of MaAbNA
on the competitive inhibition of standard ligand EGF
binding to EGFR1, thus indicating the potential of
MaAbNA to inhibit EGF-driven tumor cell proliferation.

In vitro therapeutic efficacy
In order to evaluate the therapeutic efficacy of
MaAbNA and MaAbNA-PEG2000-ADM as well as
their potential cytotoxicity, cell viability assays were
performed using tumor cell lines A549, MDA-MB-231,
MCF-7, and normal cell line L2. As shown in Figs. 7A
and B, MaAbNA and MaAbNA-PEG2000-ADM effectively reduced the viability of A549 (EGFR1- and
HER2- positive) and MDA-MB-231 (EGFR1-positive,
HER2-negative) cells. MaAbNA displayed a higher
therapeutic efficacy in A549 cells than either the
commercial antibody drugs (anti-EGFR1 Cetuximab
and anti-HER2 Herceptin) or the commonly used anticancer drug ADM (Fig. 7A). Moreover, in
MDA-MB-231 cells over-expressing only EGFR1,
MaAbNA displayed a higher therapeutic efficacy than
anti-HER2 Herceptin, but exhibited a similar efficacy

to anti-EGFR1 Cetuximab (Fig. 7B). Importantly,
MaAbNA-PEG2000-ADM exhibited higher therapeutic efficacy than ADM, MaAbNA and control antibodies in both A549 and MDA-MB-231 cells with high
receptor expression (Figs. 7A, B), highlighting its improved antitumor activity versus MaAbNA alone,
and further confirming a role for MaAbNA in delivering anti-tumor drugs to EGFR1 and/or HER2 positive
tumor
cells.
MaAbNA
and
MaAbNA-PEG2000-ADM were minimally cytotoxic
toward low receptor expression cells MCF-7 and L2
(Figs. 7C, D), so were Cetuximab and Herceptin,
whereas ADM was highly cytotoxic to all cell lines
(Fig. 7).
To further investigate the EGFR1 and HER2 targeted antitumor efficacy of MaAbNA and
MaAbNA-PEG2000-ADM, EGFR1- or HER2- knockdown A549 cells were constructed. At 48-hour
post-transfection of EGFR1- and HER2- siRNA,
EGFR1 and HER2 expressions in A549 cells were effectively knocked down, and the knockdown effects
were kept until 96-hour post-transfection, indicating
that the gene knockdown cells were suitable to be
applied in MTT assay (Fig. 8A). As shown in Figures
8C and 8D, MaAbNA and MaAbNA-PEG2000-ADM
displayed significant higher inhibitory effects on
non-transferred A549 than either EGFR1- or HER2knockdown cells. The therapeutic efficacies of
MaAbNA and its drug conjugated were consistent
with the expression level of EGFR1 and HER2,
demonstrating their specificities to both of the receptors.
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Taken together, these results suggest that
MaAbNA antibody and MaAbNA-PEG2000-ADM are
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promising anticancer drugs for EGFR1- and/or
HER2- overexpressing tumors.

Figure 6. A, the competitive inhibition of EGF cell-binding conducted by free MaAbNA, which was imaged by a laser confocal microscope. B, mean fluorescence
intensity of cells, which was detected by a laser confocal microscope. The competitive inhibition of EGF-binding to A549 (C) and MDA-MB-231 (D) cells by increasing
concentrations of free MaAbNA, which was detected by flow cytometer. Data are given as mean±SD (n=5). *P <0.05.

Figure 7. In vitro antitumor efficacy and cytotoxicity. Cell viability of A549 (A), MDA-MB-231 (B), MCF-7 (C), and L2 cells (D), incubated with MaAbNA, Cetuximab,
Herceptin, ADM or MaAbNA-PEG2000-ADM. Data are given as mean±SD (n=5).
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Figure 8. A, EGFR1 and HER2 expression in A549 cells at 48 and 96-hour post-transfection of EGFR1 or HER2 siRNA. In vitro inhibiting ability of MaAbNA and
MaAbNA-PEG2000-ADM on EGFR1 (B) and HER2 (C) knockdown A549 cells. Data are given as mean±SD (n=5). *P <0.05.

Down-regulation of oncogenes in cells
conducted by MaAbNA
C-jun and c-fos genes are regulated downstream
of EGFR1 and HER2 [51, 52]. The dimer of c-fos and
c-jun comprises the AP-1 early response transcription
factor, which is closely related to the invasive capability of tumor cells. Down-regulation of c-jun and
c-fos are important indexes of tumor therapy, therefore alterations in c-jun and c-fos transcription provides evidence for the binding function of MaAbNA
to EGFR1 and HER2, and reduced expression of these
genes will result in inhibition of downstream signaling, ultimately arresting tumor cell growth. To investigate the regulatory role of MaAbNA on tumor cell
progression, c-jun, and c-fos mRNA transcription
levels were assessed before and after MaAbNA
treatment, or after treatment with anti-EGFR1 nanobody 7D12 as a positive control (Fig. 9). Transcription
of c-jun and c-fos were significantly down-regulated
after incubation of A549 cells with MaAbNA (P<
0.05). Changes in gene expression were also observed
in A549 cells treated with the anti-EGFR1 nanobody
7D12, but to a much lesser extent than in
MaAbNA-treated cells. This is presumably due to
activation of downstream signal transduction pathways not only by binding of EGF to EGFR1 but also
by
autophosphorylation
of
heterodimeric
EGFR1/HER2 receptors in HER2-overexpressing tumors [53]. For A549 cells, which overexpress both

EGFR1 and HER2, MaAbNA is predicted to have dual-receptor targeting ability and thus exhibit a
stronger inhibitory effect on oncogenic signaling than
the monovalent anti-EGFR1 nanobody 7D12. As expected, expression of both c-fos and c-jun were similarly down-regulated in MDA-MB-231 cells treated
with MaAbNA compared to anti-EGFR1 nanobody
7D12
treatment;
however,
the
degree
of
down-regulation was lower than that observed in
A549. In A549 cells treated with MaAbNA, c-fos and
c-jun expression decreased by 73% and 72%, respectively, while in MDA-MB-231 c-fos and c-jun expression decreased by only 50% and 55%, respectively. In
comparison, gene expression decreases were 32% and
29% (A549 cells) and 53% and 62% (MDA-MB-231
cells) following nanobody treatment, and no obvious
down-regulation of c-fos or c-jun was observed in
MCF-7 cells.

Regulation of signal transduction pathways by
MaAbNA in A549 cells
Expression of the AEG-1 oncogene is closely related to tumor migration and invasion [54, 55], and is
mediated by Ha-ras and the associated signaling
pathway shown in Fig. 10A. Ha-ras activates the PI3K
signaling cascade, resulting in increased c-myc expression and binding of Myc-Max to the AEG-1 promoter, augmenting AEG-1 expression. AEG-1 activates the NF-κB pathway, which regulates expression
of genes involved in migration and invasion and thus
http://www.thno.org

Theranostics 2015, Vol. 5, Issue 4
plays a crucial role in Ha-ras-mediated tumor progression [56]. C-myc is a proto-oncogene which is
frequently found to be up-regulated in many types of
cancers. Myc overexpression stimulates gene amplification, presumably through DNA over-replication
[57].
Introduction of either c-myc or AEG-1 siRNA
similarly and effectively down-regulated AEG-1 expression, suggesting interplay between c-myc and
AEG-1 (Fig. 10B). Comparing with the non-treated
control, treatment of A549 cells (EGFR1- and HER2overexpressing) with MaAbNA effectively inhibited
c-myc and AEG-1 expression by decreasing Akt (S473)
phosphorylation, while the anti-EGFR nanobody
7D12 did not inhibit c-myc or AEG-1 oncogenes significantly (Fig. 10B), suggesting that MaAbNA could
limit cancer cell proliferation, migration and invasion
through blocking of the Ha-ras-Akt signal pathway
downstream of EGFR1 and HER2 [58]. Treatment
with MaAbNA or the nanobody induced similar inhibition of Akt (S473) phosphorylation in
MDA-MB-231 cells (EGFR1-negative, HER2-positive)
(Fig. 10C), which further confirmed the synergistic
effect of EGFR1 and HER2.

In vivo dynamic distribution and
tumor-targeting ability of MaAbNA
The in vivo dynamics of MPA-MaAbNA biodistribution is shown in Figures 11 and 12.
MPA-MaAbNA was quickly distributed throughout
the body within approximately 30 minutes after injection, was excreted by the kidneys by 4-hour
post-injection, and was largely cleared from the body
within 24 hours. In order to compare the tumor-targeting ability of MPA-MaAbNA to that of the
MPA-anti-EGFR1
nanobody
7D12
and
the
MPA-ZHER2:4 affibody, nude mice bearing tumor
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xenografts of A549, MDA-MB-231, or MCF-7 cells
were used. Fluorescence images obtained at different
time points after administration of MPA-MaAbNA,
MPA-anti-EGFR1 nanobody 7D12 and MPA-ZHER2:4
affibody in A549 tumor-bearing mice are shown in
Fig. 11A. Within 2 hours after injection of the three
probes, A549 xenografts were identifiable, and the
intense signal at tumor sites was maintained up to 24
hours after injection, after which signal intensity
gradually decreased. By 72 hours post-injection, the
fluorescent probes had cleared from the body. Tumors
in mice receiving MPA-MaAbNA displayed higher
fluorescence intensity than tumors in mice injected
with the MPA-anti-EGFR1 nanobody 7D12 or
MPA-ZHER2:4
affibody,
with
maximal
tumor/normal tissue contrast ratios of 5.09, 2.72 and
2.48, respectively (Fig. 11B). As expected, the administration of free MaAbNA antibody effectively
blocked the tumor targeting of all the three probes
(Fig. 11), confirming its affinity to EGFR1 and HER2 in
vivo.
To further explore the specificity of
MPA-MaAbNA, xenografts of MDA-MB-231 and
MCF-7 tumor cells were studied. Similar tumor-specific fluorescence signals were detected in
mice injected with MPA-MaAbNA relative to the
MPA-anti-EGFR1 nanobody 7D12 treated group (Fig.
12A), with maximal T/N ratios of 2.48 and 2.53, respectively (Fig. 12D). Free MaAbNA inhibited the
binding
of
both
MPA-MaAbNA
and
MPA-anti-EGFR1 nanobody 7D12 to tumors (Figs.
12A, D). In contrast, in MCF-7-derived tumors
MPA-MaAbNA showed no significant targeting ability (Figures 12B and 12D), consistent with the
EGFR1-negative/HER2-negative status of MCF-7
cells.

Figure 9. Down-regulation of c-jun and c-fos mRNA transcription level in A549, MDA-MB-231 and MCF-7 cells treated with MaAbNA and anti-EGFR1 nanobody
7D12. Data are given as mean±SD (n=5). *P <0.05.
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Figure 10. A, signal transduction pathways involved in Ha-ras-mediated AEG-1 induction. B, phosphorylation of Akt S473, expression of c-myc and AEG-1 regulated
by MaAbNA and anti-EGFR1 nanobody 7D12 in A549 (B) and MDA-MB-231 (C) cells.

Figure 11. A, Dynamics and tumor-targeting ability of MaAbNA, anti-EGFR1 nanobody 7D12 and ZHER2:4 affibody in A549-bearing nude mice, with or without
blocking dose of free MaAbNA. B, maximal tumor/normal tissue ratio {T/N ratio= [tumor signal background signal]/ [normal signal (muscle) background signal] ×
100%} calculated from the ROIs at 8-hour post-injection of different probes into A549 tumor-bearing mice with or without blocking dose of free MaAbNA. Data are
given as mean±SD (n=5). *P <0.05.
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Figure 12. Dynamics and tumor-targeting ability of MaAbNA and anti-EGFR1 nanobody 7D12 in MDA-MB-231-bearing (A), MCF-7-bearing (B) and normal (C) nude
mice, with or without blocking dose of free MaAbNA. D, maximal tumor/normal tissue ratio calculated from the ROIs at 8-hour post-injection of different probes into
MDA-MB-231 and MCF-7 tumor-bearing mice with or without blocking dose of free MaAbNA. Data are given as mean±SD (n=5). *P <0.05.

The plots of the maximal T/N ratios for all
groups of tumor-bearing mice indicated that
MPA-MaAbNA showed the best targeting to A549
tumors, and the nude mice bearing A549 tumors
treated with MPA-MaAbNA had a higher T/N ratio
than those treated with other univalent-specific
probes (Figs. 11B and 12D).

In vivo competitive inhibition of EGF
tumor-binding
As shown in Fig. 13, free MaAbNA effectively
inhibited the in vivo tumor-binding of MPA-EGF,
which indicated the potential ability of MaAbNA to
inhibit the EGF-driven tumor progression in vivo.

Pharmacokinetics of MaAbNA and
MaAbNA-PEG2000-ADM
The serum concentrations of MaAbNA and
MaAbNA-PEG2000-ADM at different post-injection

time are shown in Supplementary Material: Fig. S3.
Using WinNonlin software analysis, in accordance
with the two-compartment model, the pharmacokinetic parameters of the two drugs in rats are listed in
Table 2.
As indicated in Table 2, the plasma concentrations of both MaAbNA and MaAbNA-PEG2000-ADM
showed an exponential decline after intravenous administration.
The
elimination
of
MaAbNA-PEG2000-ADM occurred more slowly than
that of non-modified MaAbNA with a half-life of
19.46 ± 2.31 h, approximately 2.8 fold longer than
half-life of MaAbNA (6.9 ± 1.66 h). In contrast to
MaAbNA, MaAbNA-PEG2000-ADM showed a significant decrease in clearance (CL) and a marked increase in the area under the plasma concentration-time curve (AUC), which suggests that
MaAbNA-PEG2000-ADM is retained longer in the
blood circulation than MaAbNA. Taken together,
http://www.thno.org
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these results demonstrate that PEGylation of
MaAbNA improves its half-life in circulation, and

promotes its intravascular retention, thus decreasing
the required administration frequency.

Table 2. Pharmacokinetic properties estimated by two-compartmental model analysis following intravenous bolus injection of MaAbNA
and MaAbNA-PEG2000-ADM to rats.
PK properties
AUC0-∞ (nmol*h/L)
t1/2α (h)
t1/2β (h)
CL (L/h)
MRT (h)
Vdss (L)

MaAbNA
1044±327
0.54±0.09
6.95±2.14
0.061±0.002
6.9±1.66
0.45±0.03

MaAbNA-PEG2000-ADM
3568±722**
1.43±0.17*
19.46±2.31**
0.018±0.01**
21.2±2.48**
0.38±0.03*

Data are expressed as mean ± SD (n = 6). *P < 0.05, **P < 0.01, MaAbNA vs MaAbNA-PEG2000-ADM. Abbreviations: AUC, area under the curve; CL, clearance; MRT, mean
residence time; Vdss, steady state volume of distribution.

Figure 13. The tumor-binding block of EGF in A549-bearing (A) and MDA-MB-231-bearing (B) nude mice, which was conducted by free MaAbNA. C, maximal
tumor/normal tissue ratio calculated from the ROIs at 8-hour post-injection of MPA-EGF into different tumor-bearing mice with or without blocking dose of free
MaAbNA. Data are given as mean±SD (n=5). *P <0.05.

In vivo antitumor efficacy of MaAbNA
In vivo antitumor efficacy of MaAbNA and
MaAbNA-PEG2000-ADM
were
evaluated
in
A549-bearing nude mice by measuring the tumor
growth of the mice. As shown in Fig. 14A and B, tumors in saline-treated mice grew faster than those of

the
ADM,
Cetuximab,
Herceptin,
MaAbNA-PEG2000-ADM or MaAbNA-treated mice.
Administration of MaAbNA reduced the tumor
volume by 58% after 15 days of treatment. This decrease was higher than that in ADM (~47%) and Cetuximab (~36%)-treated mice, but was lower than that
observed in Herceptin-treated mice (~70% decrease).
http://www.thno.org
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Treatment with MaAbNA-PEG2000-ADM reduced
tumor volume by 78%, the greatest extent of tumor
reduction in any of the groups. Moreover, the body
weights of mice in different groups gradually increased within the treatment period, indicating no
apparent physical toxicity, but a decrease of body
weight (1.2 g) in the ADM-treated group was observed after 13 days treatment (Fig. 14C). The 15-day
survival rates of mice in the MaAbNA,
MaAbNA-PEG2000-ADM and Herceptin-treated
groups were 100%, and that in Cetuximab and ADM
groups were 83.3% and 66.7% respectively, whereas
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the survival rate of the saline group was drastically
decreased to 33.3% (Fig. 14D). Histological analysis of
tumor tissues was used to further confirm the anti-cancer efficacy of MaAbNA (Fig. 14E). Compared to
saline-treated control, significant amounts of necrotic
tissue were observed in tumors of all the other
groups. Furthermore, the extent of tumor necrosis in
the MaAbNA-PEG2000-ADM group was higher than
that in tumors treated with any other drugs, which
was consistent with our in vitro cytotoxicity results in
A549 cells over-expressing EGFR1 and HER2.

Figure 14. Therapeutic efficacy of MaAbNA in A549 tumor-bearing nude mice. A, tumor volumes of mice under different treatments (saline, MaAbNA, Cetuximab,
Herceptin, ADM and MaAbNA-ADM, n= 6/group). B, tumors separated from mice under different treatments. C, body weights of mice in different groups. D, the
15-day survival rates of mice after administration of different drugs. E, the tissue slices of tumors in different groups. The tissue slices of hearts (F) and kidneys (G) in
saline, MaAbNA-PEG2000-ADM and ADM-treated groups. Data are given as mean±SD (n=5). *P <0.05.
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Heart is the main organ affected by free ADM,
and the body accumulation of ADM was reported to
result in significant cardiotoxicity [59]. In addition, the
free ADM and MaAbNA were approved to be cleared
out of the body through kidney. Therefore, to investigate the side effects of MaAbNA-PEG2000-ADM,
cardiac and renal histological analyses of the treated
mice were conducted. Sections of myocardium (Fig.
14F) demonstrated that, compared with the saline
control, no distinct pathologic changes were found in
the hearts of MaAbNA-PEG2000-ADM-treated mice.
In contrast, the hearts of 2 members in the
ADM-treated group showed noticeable pathologic
changes, indicating that the MaAbNA ligand specifically carried ADM molecules to the tumors
over-expressing EGFR1 and HER2, thus reduced the
body-accumulation and toxic side effect of ADMs.
Besides, no significant nephrotoxicity was observed in
either MaAbNA-PEG2000-ADM or free ADM-treated
mice (Fig. 14G).

Discussion
Several factors determine whether a molecular
probe is appropriate for a given biological process or
disease state, such as its pharmacokinetics, possible
interactions that may results in increased non-specific
signal, correlation between intensity of the probe
signal and the levels of molecular target, and low cytotoxicity. Recently, various engineered protein
probes, particularly antibody fragments, protein
scaffolds and natural protein ligands with more
compact size, shorter clearance time, and better tumor
penetration are finding their way in early stage diagnosis, therapeutic response monitoring, and personalized treatment [60]. To explore the efficacy of a
novel tumor-targeting ligand with high affinity and
specificity for tumor cells, a 29 kDa antibody
(MaAbNA), composed of one anti EGFR1 nanobody
7D12 and two ZHER2:4 affibodies, was developed
and shown to possess high affinity for EGFR1 (~4.1
nM) and HER2 (~4.7 nM). And similar affinity for
EGFR1 (~6.9 nM) and HER2 (~7.2 nM) was also possessed by its derivative MaAbNA-PEG2000-ADM.
This bispecific biomolecule was approved to bind to
both EGFR1 and HER2, which are over-expressed in
variety of tumor cells. The avidity of MaAbNA to
tumor cells was evaluated using three tumor cell lines
with defined expression of EGFR1 and HER2 receptor
tyrosine
kinases:
A549
(EGFR1-positive,
HER2-positive),
MDA-MB-231
(EGFR1-positive,
HER2-negative), and MCF7 (EGFR1-negative,
HER2-negative) (Figs. 4, 5). The in vivo tumor targeting ability of MaAbNA was consistent with our in
vitro data and indicated that MaAbNA specifically
targeted to A549 and MDA-MB-231 xenografts, with
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maximal T/N contrast ratios of 5.09 and 2.48, respectively, at 8 hours post injection, while MaAbNA displayed poor targeting ability for the receptor-negative
MCF-7 (Figs. 11, 12). Moreover, both the in vitro and in
vivo binding of anti-EGFR1 nanobody 7D12 and
ZHER2:4 affibody to receptors was successfully
blocked by free MaAbNA. These results strongly
suggest that MaAbNA has high affinity and selectivity for tumor cells overexpressing EGFR1 and/or
HER2, which further solidifies the potential of using
MaAbNA as a molecular probe for tumor targeting.
In vitro MTT assays indicated that MaAbNA exhibited selective toxicity for A549 and MDA-MB-231
cells, but was non-cytotoxic toward MCF-7 cells and
the non-malignant cell line L2 (Fig. 7). In contrast,
adriamycin (ADM) was toxic to all cell lines investigated. In A549 cells, MaAbNA was more cytotoxic
than either antibody controls (Cetuximab and Herceptin) or adriamycin. Additionally, after modification
with
ADM,
the
ability
of
MaAbNA-PEG2000-ADM to inhibit A549 cell growth
was increased, due to the receptor targeting ability of
MaAbNA. Moreover, as shown in Fig. 8, both
MaAbNA and MaAbNA-PEG2000-ADM displayed
significant lower therapeutic efficacy on either
EGFR1- or HER2- knockdown A549 cells than those
on non-transferred cells, further confirming their selective
cytotoxicity
toward
tumor
cells
over-expressing EGFR1 and HER2. Furthermore,
evaluation of the in vivo antitumor therapeutic efficacy
(Fig. 14) showed that the antitumor activity of
MaAbNA was higher than that of ADM and anti-EGFR1 Cetuximab, but was lower than that of
Herceptin, inconsistent with its higher in vitro efficacy
than Herceptin. This is mainly because MaAbNA
molecule lacks Fc portion possessed by Herceptin,
which could be combined with NK cells (nature killer
cells), thus leading to an antibody-dependent
cell-mediated cytotoxicity (ADCC) in vivo [61]. However, MaAbNA-PEG2000-ADM conjugation has
overcome this limitation (Fig. 14), suppressed the
proliferation of A549 xenografts to a greater extent
than either control antibodies (Cetuximab and Herceptin) or ADM and MaAbNA alone. Moreover, the
15-day survival rates of mice treated with MaAbNA
or MaAbNA-PEG2000-ADM were 100%, whereas
only 33.3% of saline-treated tumor-bearing mice remained alive after 15 days. In contrast to the saline-treated control, MaAbNA and its derivative
MaAbNA-PEG2000-ADM efficiently inhibited tumor
growth, thus prolonging survival time. Both in vitro
and in vivo studies confirmed the therapeutic efficiency of MaAbNA and MaAbNA-PEG2000-ADM in
EGFR1-positive and HER2-positive tumors. Besides,
from the sections of myocardium, noticeable cardiohttp://www.thno.org
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toxicity occurred in the ADM-treated mice (Fig. 14F),
which may result in their body weight decreasing
after 13-day treatment of ADM (Fig. 14C). However,
this
cardiotoxicity
was
not
observed
in
MaAbNA-PEG2000-ADM-treated group, indicating
that the conjugated MaAbNA specifically delivered
ADMs to tumor tissues, thus reduced the side effects
of ADM, further demonstrating its selective targeting
to EGFR1 and HER2 receptors. The PEG2000 modification also had the benefit of prolonging the half-life
of MaAbNA in circulation, which decreased the administration frequency of the PEG2000-ADMmodified antibody.
Binding of EGF to the extracellular domain of
EGFR1 induces receptor dimerization and subsequent
activation of its intracellular tyrosine kinase domain,
which leads to the activation of numerous downstream signaling pathways, driving cell proliferation
and other cellular responses. EGFR1 signaling is
tightly controlled in normal cells, however the aberrant overexpression of EGFR1 in tumor cells caused
by amplification of the EGFR1 gene, over-production
of EGF that results in abnormal autocrine or paracrine
stimulation, or by mutations that increase the receptor's tyrosine kinase activity all promote cell proliferation, differentiation, angiogenesis and inhibition of
apoptosis, thus favoring tumor growth and metastasis
[62]. In this study, MaAbNA competed with EGF to
bind EGFR1 (Figs. 6 and 13), which blocked the activation of EGF-EGFR1 downstream signaling pathway
and inhibited tumor cell growth. The activity of HER2
in cell signaling is mediated by HER2 heterodimerization with other HER-family receptors and subsequent tyrosine phosphorylation of the intracellular
domain of HER2 [63]. It is now recognized that HER2
can recruit a diverse set of intracellular signaling
molecules by heterodimerizing with EGFR1 [64].
Therefore, tumors with both EGFR1 and HER2
over-expression are more invasive, and can be accompanied by c-myc overexpression [65, 66], which is
closely associated with AEG-1 expression. Our miniature MaAbNA antibody blocked EGFR1 binding to
EGF and also blocked the dimerization of EGFRs mediated by HER2, thus preventing activation of both
the EGFR1 and HER2 signaling pathway
(Ras/Raf/MEK/ERK and PI3K/Akt) [67]. MaAbNA
also inhibited expression of c-jun, c-fos, c-myc and
AEG-1, whose expression positively correlates with
tumor cell proliferation and metastasis (Figs. 9 and
10). Our results confirm that MaAbNA has the capacity to inhibit cancer cell proliferation, migration and
invasion, indicating therapeutic potential for
MaAbNA in metastatic cancers [68]. On the other
hand, the poor oncogene-regulating ability of anti-EGFR1 nanobody confirms the inhibition of
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MaAbNA due to the synergistic effect of EGFR1 and
HER2.
In this study, we have used both in vitro and in
vivo approaches to investigate the tumor-targeting
and anticancer capability of MaAbNA, as well as to
demonstrate the feasibility of the dual targeting approach. However, further studies are needed for
MaAbNA to clinical applicability. Immunogenicity is
an important index to estimate the clinical feasibility
of antibodies. Although the anti-EGFR1 nanobody
was reported to have no immunogenicity in preclinical and clinical tests [30, 69], the risk of immunogenicity of MaAbNA still exists due to the Staphylococcus
origin of the affibody molecules. The ABD method
(human albumin-binding domain) has been used for
modification of humanized forms of affibodies [70].
After tagging with ABD, affibodies display no immunogenicity in human serum, which is beneficial for
use in in vivo tumor imaging and targeting. A variety
of other technologies and methods [71] could be
adapted to reduce the immunogenicity of MaAbNA,
including humanized reform and PEGylation [72],
which would be conducive to the sequence and
structure optimization of MaAbNA for potential clinical applications. Moreover, the side effects of
MaAbNA and MaAbNA-PEG2000-ADM were not
comprehensively investigated in this study, although
they exhibited no apparent physical toxicity in mice
(Fig. 14C). That is because no conclusive evidence
indicated that the human-receptor specific antibody
had the similar affinity to the murine receptors, which
was also verified in our preliminary experiment, the
targeting ability of MaAbNA to the murine EAC
xenografts was not as good as that to the human A549
xenografts over-expressing EGFR1 and HER2. Consequently, the physical toxicity should be evaluated
on cynomolgus (Macaca fascicularis) monkeys, which
are the most relevant species for toxicological studies
of the anti-EGFRs antibodies [73, 74]. Besides, our
future work includes X-ray single crystal diffraction
studies of the protein spatial structure and folding of
MaAbNA, optimization of the MaAbNA formulation
for optimal administration, as well as to study the
pharmacokinetics in different in vivo model systems,
and to reform the sequence of this antibody to improve its targeting efficiency.

Conclusion
MaAbNA exhibited significant tumor-targeting
capability in EGFR1-positive and/or HER2-positive
tumors,
with
minimal
toxicity
toward
EGFR1/HER2-negative cells and non-malignant cells,
and represents a potential antitumor agent in
EGFR1-positive and/or HER2-positive cancer cells. In
vitro and in vivo studies indicated that MaAbNA
http://www.thno.org
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showed a good anti-tumor efficacy in EGFR1-positive
and/or HER2-positive cancer cells, such as A549 and
MDA-MB-231, with minimal cytotoxicity in
non-tumor cells (L2). Moreover, conjugation of
MaAbNA to ADM significantly enhanced its tumor
lethality, inducing a better selective antineoplastic
efficacy on EGFR1- and/or HER2- overexpressing
cancer cells than ADM, Cetuximab and Herceptin.
Overall, our results demonstrate that the MaAbNA
bispecific antibody is a promising theranostic biomolecule for molecular imaging and targeted treatment of EGFR1/HER2- expressing tumors.
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